Monk, B. J., Kauderer, J. T., Moxley, K. M., Bonebrake, A. J., Dewdney, S. B., Secord, A. A., . . . Aghajanian, C. (2018). A phase II evaluation of elesclomol sodium and weekly paclitaxel in the treatment of recurrent or persistent platinum-resistant ovarian, fallopian tube or primary peritoneal cancer: An NRG oncology/gynecologic oncology group study. Gynecologic oncology, 151(3), 422-427. https://doi.org/10.1016/j.ygyno.2018.10.001
Citace podle Chicago (17th ed.)Monk, Bradley J., James T. Kauderer, Katherine M. Moxley, Albert J. Bonebrake, Summer B. Dewdney, Angeles Alvarez Secord, Frederick R. Ueland, Carolyn M. Johnston, a Carol Aghajanian. "A Phase II Evaluation of Elesclomol Sodium and Weekly Paclitaxel in the Treatment of Recurrent or Persistent Platinum-resistant Ovarian, Fallopian Tube or Primary Peritoneal Cancer: An NRG Oncology/gynecologic Oncology Group Study." Gynecologic Oncology 151, no. 3 (2018): 422-427. https://doi.org/10.1016/j.ygyno.2018.10.001.
Citace podle MLA (9th ed.)Monk, Bradley J., et al. "A Phase II Evaluation of Elesclomol Sodium and Weekly Paclitaxel in the Treatment of Recurrent or Persistent Platinum-resistant Ovarian, Fallopian Tube or Primary Peritoneal Cancer: An NRG Oncology/gynecologic Oncology Group Study." Gynecologic Oncology, vol. 151, no. 3, 2018, pp. 422-427, https://doi.org/10.1016/j.ygyno.2018.10.001.